
Loulieta Nazerai/LinkedIn
Mar 19, 2025, 12:03
Changing the treatment landscape for patients with resistant melanoma – Danish Cancer Institute
Danish Cancer Institute posted on LinkedIn about recent paper by Loulieta Nazerai et al., titled “Thiopurine therapy enhances immune checkpoint inhibitor efficacy in low-mutational burden melanoma: A promising anticancer approach” published on PNAS.
Authors: Loulieta Nazerai, Christina Tsiavou, Lina Vardouli, Kjeld Schmiegelow, and Daniela De Zio
“‘I hope my research will improve the options for patients who don’t have many options at the moment.’
Meet Loulieta Nazerai, Postdoc in the Melanoma Research Team led by Daniela De Zio.
Loulieta specialises in cancer immunotherapy, and recently her research led to an important discovery that could change the treatment landscape for patients with resistant melanoma.”
Video attached to the post.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 19, 2025, 11:59
Mar 19, 2025, 11:38
Mar 19, 2025, 11:01
Mar 19, 2025, 10:48
Mar 19, 2025, 10:08
Mar 19, 2025, 10:01
Mar 19, 2025, 09:50